Trimedyne Competitors

Trimedyne (OTCMKTS:TMED) and Medtronic (NYSE:MDT) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 11.1% of Trimedyne shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Trimedyne and Medtronic, as reported by MarketBeat.com.

Medtronic has a consensus price target of $124.2692, indicating a potential upside of 0.30%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Trimedyne.

Profitability

This table compares Trimedyne and Medtronic's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Trimedyne and Medtronic's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Trimedyne.

Summary

Medtronic beats Trimedyne on 10 of the 11 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Sonova (OTCMKTS:SONVY) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

1.1% of Sonova shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Sonova, as reported by MarketBeat.com.

Profitability

This table compares Trimedyne and Sonova's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Trimedyne and Sonova's top-line revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than Trimedyne.

Summary

Sonova beats Trimedyne on 5 of the 6 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Varian Medical Systems (NYSE:VAR) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Varian Medical Systems, as reported by MarketBeat.com.

Varian Medical Systems has a consensus price target of $159.3571, indicating a potential downside of 10.04%. Given Varian Medical Systems' higher probable upside, analysts plainly believe Varian Medical Systems is more favorable than Trimedyne.

Profitability

This table compares Trimedyne and Varian Medical Systems' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Trimedyne and Varian Medical Systems' top-line revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than Trimedyne.

Summary

Varian Medical Systems beats Trimedyne on 8 of the 9 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Masimo (NASDAQ:MASI) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Trimedyne and Masimo's net margins, return on equity and return on assets.

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.1% of Trimedyne shares are held by insiders. Comparatively, 11.5% of Masimo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trimedyne and Masimo, as reported by MarketBeat.com.

Masimo has a consensus price target of $272.20, indicating a potential upside of 13.67%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than Trimedyne.

Earnings and Valuation

This table compares Trimedyne and Masimo's top-line revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Trimedyne.

Summary

Masimo beats Trimedyne on 10 of the 10 factors compared between the two stocks.

Trimedyne (OTCMKTS:TMED) and Getinge (OTCMKTS:GNGBY) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Trimedyne and Getinge's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.0% of Getinge shares are owned by institutional investors. 11.1% of Trimedyne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Trimedyne and Getinge's revenue, earnings per share and valuation.

Getinge has higher revenue and earnings than Trimedyne.

Analyst Recommendations

This is a breakdown of current ratings for Trimedyne and Getinge, as provided by MarketBeat.

Summary

Getinge beats Trimedyne on 8 of the 9 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Trimedyne (OTCMKTS:TMED) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by insiders. Comparatively, 11.1% of Trimedyne shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for LivaNova and Trimedyne, as reported by MarketBeat.com.

LivaNova currently has a consensus price target of $69.3333, indicating a potential downside of 14.83%. Given LivaNova's higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Trimedyne.

Profitability

This table compares LivaNova and Trimedyne's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares LivaNova and Trimedyne's top-line revenue, earnings per share (EPS) and valuation.

Trimedyne has lower revenue, but higher earnings than LivaNova.

Summary

LivaNova beats Trimedyne on 7 of the 10 factors compared between the two stocks.